Division of Plastic, Reconstructive & Aesthetic Surgery, Department of Surgery, University of Toronto, Toronto ON, Canada.
Faculty of Medicine, University of Toronto, Toronto ON, Canada.
J Plast Reconstr Aesthet Surg. 2024 Dec;99:110-121. doi: 10.1016/j.bjps.2024.09.022. Epub 2024 Sep 11.
Patient-reported outcomes (PROs) are key to investigating patient perspectives in randomized controlled trials (RCTs). Standardization of PRO reporting is critical for trial generalizability and the application of findings to clinical practice. This systematic review aimed to evaluate the reporting quality of RCTs published in the top plastic surgery journals according to the consolidated standards of reporting trials (CONSORT)-PRO extension.
We completed a comprehensive search of MEDLINE, Embase, and Cochrane Central Register of Controlled Trials. All RCTs with a validated PRO endpoint published in the top 10 plastic surgery journals (based on the 2021 Web of Science Impact Factor) from 2014 to 2023 were included. Two reviewers independently extracted data and scored the included studies using the CONSORT-PRO checklist. Univariate regression was applied to assess factors associated with reporting adherence. Studies were assessed for their risk of bias using the Cochrane Risk of Bias 2.0 tool.
A total of 88 RCTs were included. PROs were the primary endpoint in 50 (57%) and the secondary endpoint of 38 (43%) studies. Mean overall reporting adherence was poor (39% (±12) and 36% (±13) in studies with PRO as primary and secondary endpoints, respectively). The presence of industry support was significantly associated with greater adherence.
There is low adherence to the CONSORT-PRO extension among plastic surgery RCTs published in the top 10 plastic surgery journals. We encourage journals and authors to endorse and apply the CONSORT-PRO extension. This may optimize the dissemination of clinical findings from RCTs and assist patient-centered care.
患者报告结局(PROs)是研究随机对照试验(RCTs)中患者观点的关键。PRO 报告的标准化对于试验的普遍性和研究结果在临床实践中的应用至关重要。本系统评价旨在根据 CONSORT-PRO 扩展评估发表在顶级整形外科杂志上的 RCT 的报告质量。
我们对 MEDLINE、Embase 和 Cochrane 对照试验中心注册库进行了全面检索。纳入了 2014 年至 2023 年期间在顶级 10 个整形外科杂志(基于 2021 年 Web of Science 影响因子)上发表的具有验证性 PRO 终点的所有 RCT。两名评审员独立提取数据,并使用 CONSORT-PRO 清单对纳入的研究进行评分。应用单变量回归评估与报告依从性相关的因素。使用 Cochrane 偏倚风险 2.0 工具评估研究的偏倚风险。
共纳入 88 项 RCT。PRO 是 50 项(57%)研究的主要终点,是 38 项(43%)研究的次要终点。整体报告依从性平均值较差(分别为 PRO 作为主要和次要终点的研究中为 39%(±12)和 36%(±13))。有工业支持的研究明显与更高的依从性相关。
在顶级 10 个整形外科杂志上发表的整形外科 RCT 中,CONSORT-PRO 扩展的依从性较低。我们鼓励杂志和作者认可并应用 CONSORT-PRO 扩展。这可能会优化 RCT 临床发现的传播,并有助于以患者为中心的护理。